跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
Approvals
/
Health Canada
/
TABRECTA
Authorized
STANDARD
TABRECTA
novartis pharmaceuticals canada inc
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
4369416c86cfca9b
Company
novartis pharmaceuticals canada inc
Type
Standard
Approval Details
Approval Id
4369416c86cfca9b
Drug Approval Canada Name
TABRECTA
Product Name
TABRECTA
Status
Marketed
Status Date
2022-09-16
Original Market Date
2022-09-16
Din
02527405
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
10:00.00
Atc Original
L01EX17 CAPMATINIB
Atc Name
l 01 ex 17
Aig Number
0163681002
Company Name
novartis pharmaceuticals canada inc
Company Address
100, 700 Rue Saint-Hubert, Montreal, Quebec, Canada, H2Y 0C1
Active Ingredients
CAPMATINIB (CAPMATINIB HYDROCHLORIDE)
200 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
4369416c86cfca9b
Type
Standard
Back to Health Canada Approvals
TABRECTA - Health Canada Drug Approval Details